Sygnis Pharma AG announces date for presentation of clinical results
...IDELBERG, Germany, 11 July 2007 – On 23 July sygnis Pharma AG will present the results of the clinical...ke place on 28 November 2007 in Eppelheim. About sygnis Pharma sygnis Pharma AG, with head offices in Heidelberg, is a s...TGen and ASU researchers find drug that could reduce risk of Alzheimer's
...y have no competing financial interests. Four of the authors hold stock in sygnis Pharma AG, a German pharmaceutical company that owns the rights to develop this drug class as a potential memory enhancer. They stated that sygnis was not directly involved in this study, did not fund any part of it, and d...Brain protein improves stroke symptoms in rats, even when injected after 3 days
...humans. The BMC Biology study is the first to show that G-CSF can be effective when injected this late after a stroke event. Armin Schneider from sygnis Bioscience AG (formerly known as Axaron Bioscience AG) in Heidelberg, Germany, and Wolf-Rüdiger Schäbitz from the Neurology department in Münster, Ger...SYGNIS Pharma AG - The Company
SYGNIS Pharma AG, Heidelberg, is a specialist pharmaceutical company listed on ... In doing so, SYGNIS takes a dual therapeutic approach that aims to effect both ...SYGNIS Pharma AG - Amnestix Inc.
... with its own CNS-expertise SYGNIS is securing the future input of ... In addition SYGNIS gains direct access to the leading neurogenomic expertise of TGen. ...LIO - SYGNIS Pharma AG - Google Finance
Get the latest on SYGNIS Pharma AG (LIO) including up to date news, high quality discussion groups and more on Google Finance.=> EANS-News: SYGNIS treibt die Entwicklung von AX200 im ersten Quartal ...
SYGNIS advances development of AX200 in Q1 2009/2010, : SYGNIS Pharma AG published its financial results for the first quarter of the fiscal year 2009/2010, which ...SYGNIS Pharma buy, 10.08.2009 - Nachrichten / News von finanztreff.de
News and press releases from the pharmaceutical industry. ... In the past year SYGNIS has made significant progress in the development of ...SYGNIS advances development of AX200 in Q1 2009/2010 - News Press ...
News and press releases from the pharmaceutical industry. ... as well as obtaining necessary regulatory approvals, SYGNIS initiated a phase II efficacy ...